Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuampin vs Atorvastatin/Amlodipine in Hypertension with Dyslipidemia
NCT03951207Phase 4Completed
- Sponsor
- Yuhan
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin + rifampin in dyslipidemia and hypertension (HTN) (3 arms), sponsored by Yuhan. Primary endpoint: Rate of change in LDL-Cholesterol from baseline at 8 weeks. Started May 2019; status: completed.
02
Drugs
rosuvastatin + rifampin
03
Conditions
dyslipidemiahypertension (HTN)
Beyond the preview
Go deeper on NCT03951207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951207.